Lazari Capital Management Inc. Decreases Stake in Mesoblast Limited (NASDAQ:MESO)

Lazari Capital Management Inc. decreased its holdings in Mesoblast Limited (NASDAQ:MESO) by 15.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,467 shares of the company’s stock after selling 8,000 shares during the quarter. Lazari Capital Management Inc.’s holdings in Mesoblast were worth $371,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Mesoblast by 50.1% in the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after purchasing an additional 1,663 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares in the last quarter. Perkins Coie Trust Co acquired a new stake in shares of Mesoblast in the 2nd quarter worth approximately $68,000. Pine Valley Investments Ltd Liability Co purchased a new position in Mesoblast in the 2nd quarter valued at approximately $80,000. Finally, Rathbones Group PLC purchased a new position in shares of Mesoblast in the second quarter valued at $95,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Analyst Ratings Changes

MESO has been the topic of several recent research reports. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, September 24th. Piper Sandler upgraded Mesoblast from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, StockNews.com lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Mesoblast Trading Down 2.2 %

Shares of Mesoblast stock opened at $9.44 on Wednesday. Mesoblast Limited has a fifty-two week low of $1.61 and a fifty-two week high of $11.05. The business’s fifty day moving average is $7.55 and its two-hundred day moving average is $7.16. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm has a market cap of $1.08 billion, a PE ratio of -8.42 and a beta of 3.47.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.